Filtered By:
Drug: Warfarin
This page shows you your search results in order of date. This is page number 8.
Order by Relevance | Date
Total 3463 results found since Jan 2013.
Direct Oral Anticoagulants Versus Vitamin K Antagonist (Warfarin) For Stroke Prevention In Frail Patients With Atrial Fibrillation: A Meta-Analysis
Proc (Bayl Univ Med Cent). 2022 Dec 22;36(2):274-275. doi: 10.1080/08998280.2022.2155926. eCollection 2023.NO ABSTRACTPMID:36876251 | PMC:PMC9980567 | DOI:10.1080/08998280.2022.2155926
Source: Baylor University Medical Center Proceedings - March 6, 2023 Category: Universities & Medical Training Authors: Rupak Desai Aobo Li Avilash Mondal Priya Shenwai Bhavyasri Merugu Frailyn J Nunez Guzman Akhil Jain Source Type: research
The importance of time in therapeutic range of warfarin for stroke prevention in atrial fibrillation
Kardiol Pol. 2023;81(2):105-106. doi: 10.33963/KP.a2023.0050.NO ABSTRACTPMID:36866399 | DOI:10.33963/KP.a2023.0050
Source: Kardiologia Polska - March 3, 2023 Category: Cardiology Authors: Tze-Fan Chao Chih-Min Liu Jo-Nan Liao Source Type: research
Drug-drug interactions with direct oral anticoagulants for the prevention of ischemic stroke and embolism in atrial fibrillation: a narrative review of adverse events
Expert Rev Clin Pharmacol. 2023 Mar 2. doi: 10.1080/17512433.2023.2187376. Online ahead of print.ABSTRACTINTRODUCTION: In randomized trials, direct oral anticoagulants (DOAC) were non-inferior to the vitamin-K-antagonist (VKA) warfarin in preventing stroke/embolism in patients with atrial fibrillation (AF). DOAC are substrates for P-glycoprotein (P-gp), CYP3A4 and CYP2C9. The activity of these enzymes is modulated by several drugs which might induce pharmacokinetic drug-drug interactions (DDI). Drugs affecting platelet function have the potential for pharmacodynamic DDI of DOAC.AREAS COVERED: The literature was searched fo...
Source: Expert Review of Clinical Pharmacology - March 2, 2023 Category: Drugs & Pharmacology Authors: Claudia St öllberger Birke Schneider Josef Finsterer Source Type: research
Comparison of Efficacy and Safety of Direct Oral Anticoagulants and Warfarin between Patients in Asian and non-Asian Regions: A Systematic Review and Meta-Regression Analysis
Clin Pharmacol Ther. 2023 Mar 2. doi: 10.1002/cpt.2881. Online ahead of print.ABSTRACTDirect oral anticoagulants (DOACs) have increasingly replaced warfarin for treating patients with non-valvular atrial fibrillation (NVAF). DOACs have been demonstrated to be more useful than warfarin which was highlighted at its ethnic differences in efficacy and safety; however, the regional differences of DOACs remain unclear. We conducted a systematic review, meta-analysis, and meta-regression to evaluate the efficacy and safety of DOACs in patients from Asian and non-Asian regions with NVAF. We systematically searched randomized contr...
Source: Clinical Pharmacology and Therapeutics - March 2, 2023 Category: Drugs & Pharmacology Authors: Kaori Ambe Ayu Akita Jie Wei Yuka Yoshii Mayu Onishi Masahiro Tohkin Source Type: research
Drug-drug interactions with direct oral anticoagulants for the prevention of ischemic stroke and embolism in atrial fibrillation: a narrative review of adverse events
Expert Rev Clin Pharmacol. 2023 Mar 2. doi: 10.1080/17512433.2023.2187376. Online ahead of print.ABSTRACTINTRODUCTION: In randomized trials, direct oral anticoagulants (DOAC) were non-inferior to the vitamin-K-antagonist (VKA) warfarin in preventing stroke/embolism in patients with atrial fibrillation (AF). DOAC are substrates for P-glycoprotein (P-gp), CYP3A4 and CYP2C9. The activity of these enzymes is modulated by several drugs which might induce pharmacokinetic drug-drug interactions (DDI). Drugs affecting platelet function have the potential for pharmacodynamic DDI of DOAC.AREAS COVERED: The literature was searched fo...
Source: Expert Review of Clinical Pharmacology - March 2, 2023 Category: Drugs & Pharmacology Authors: Claudia St öllberger Birke Schneider Josef Finsterer Source Type: research
